Steven Cohen Fulcrum Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.7 - $12.0 $1.5 Million - $2.68 Million	223,400 New	223,400 $2.11 Million
Q2 2023 Aug 14, 2023	SELL	$2.26 - $3.8 $1.68 Million - $2.83 Million	-743,704 Reduced 28.13%	1,899,968 $6.27 Million
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $7.48 Million - $37 Million	2,643,672 New	2,643,672 $7.53 Million
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $2.43 Million - $4.5 Million	-494,797 Reduced 24.88%	1,494,003 $12.1 Million
Q2 2022 Aug 15, 2022	BUY	$4.2 - $24.0 $6.99 Million - $39.9 Million	1,663,800 Added 511.94%	1,988,800 $9.75 Million
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $1.8 Million - $4.27 Million	-180,655 Reduced 35.73%	325,000 $7.69 Million
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $5.12 Million - $10.4 Million	365,655 Added 261.18%	505,655 $8.95 Million
Q3 2021 Nov 15, 2021	SELL	$7.28 - $30.97 $3.01 Million - $12.8 Million	-412,885 Reduced 74.68%	140,000 $3.95 Million
Q2 2021 Aug 16, 2021	SELL	$8.09 - $12.0 $180,900 - $268,332	-22,361 Reduced 3.89%	552,885 $5.79 Million
Q1 2021 May 17, 2021	SELL	$10.94 - $15.32 $8.35 Million - $11.7 Million	-762,877 Reduced 57.01%	575,246 $6.78 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $13.4 $1.35 Million - $2.3 Million	-171,877 Reduced 11.38%	1,338,123 $15.7 Million
Q3 2020 Nov 16, 2020	BUY	$7.22 - $20.7 $9.02 Million - $25.9 Million	1,249,303 Added 479.22%	1,510,000 $12 Million
Q2 2020 Aug 14, 2020	BUY	$9.11 - $22.06 $2.37 Million - $5.75 Million	260,697 New	260,697 $4.77 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $237M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.